Minerva Neurosciences (NERV) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Minerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates
March 13, 2017 7:30 AM EDTMultiple positive data readouts during 2016 provide foundation for initiation of advanced clinical trials with three product candidates in 2017Â Â
Management to host conference call today at 8:30 a.m. Eastern Time
WALTHAM, Mass., March 13, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, today reported key business updates and financial results for the fourth quarter and fiscal year ended December 31, 2016.
... More